Friedenstein, A. J., Piatetzky-Shapiro, I. I. & Petrakova, K. V. Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 16, 381–390 (1966).
Friedenstein, A. J., Petrakova, K. V., Kurolesova, A. I. & Frolova, G. P. Heterotopic transplants of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6, 230–247 (1968).
Caplan, A. I. Mesenchymal stem cells. J. Orthop. Res. 9, 641–650 (1991).
Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).
Miwa, H. & Era, T. Tracing the destiny of mesenchymal stem cells from embryo to adult bone marrow and white adipose tissue via Pdgfrα expression. Development 145, dev155879 (2018).
Phinney, D. G. & Pittenger, M. F. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells 35, 851–858 (2017).
Willis, G. R., Kourembanas, S. & Mitsialis, S. A. Toward exosome-based therapeutics: isolation, heterogeneity, and fit-for-purpose potency. Front. Cardiovasc. Med. 4, 63 (2017).
van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).
Davies, J. E., Walker, J. T. & Keating, A. Concise review: Wharton’s jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Transl. Med. 6, 1620–1630 (2017).
Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301–313 (2008).
Ankrum, J. & Karp, J. M. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 16, 203–209 (2010).
Murray, I. R. et al. Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell. Mol. Life Sci. 71, 1353–1374 (2014).
Hardy, W. R. et al. Transcriptional networks in single perivascular cells sorted from human adipose tissue reveal a hierarchy of mesenchymal stem cells. Stem Cell 35, 1273–1289 (2017).
Kramann, R. et al. Adventitial MSC-like cells are progenitors of vascular smooth muscle cells and drive vascular calcification in chronic kidney disease. Cell Stem Cell 19, 628–642 (2016).
Bautch, V. L. Stem cells and the vasculature. Nat. Med. 17, 1437–1443 (2011).
Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
Crabbé, M. A. E. et al. Using miRNA-mRNA interaction analysis to link biologically relevant miRNAs to stem cell identity testing for next-generation culturing development. Stem Cells Transl. Med. 5, 709–722 (2016).
Morikawa, S. et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. 206, 2483–2496 (2009).
Lee, W. C. et al. Multivariate biophysical markers predictive of mesenchymal stromal cell multipotency. Proc. Natl Acad. Sci. USA 111, E4409–E4418 (2014).
Liu, S. et al. Manufacturing differences affect human bone marrow stromal cell characteristics and function: comparison of production methods and products from multiple centers. Sci. Rep. 7, 46731 (2017).
Zhao, Q. et al. MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc. Natl Acad. Sci. USA 112, 530–535 (2015).
Miura, M. et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24, 1095–1103 (2006).
Stenderup, K., Justesen, J., Clausen, C. & Kassem, M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33, 919–926 (2003).
Kuriyan, A. E. et al. Vision loss after intravitreal injection of autologous ‘stem cells’ for AMD. N. Engl. J. Med. 376, 1047–1053 (2017).
Lalu, M. M. et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 7, e47559 (2012).
Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829–834 (2010).
Prockop, D. J., Oh, J. Y. & Lee, R. H. Data against a common assumption: xenogeneic mouse models can be used to assay suppression of immunity by human MSCs. Mol. Ther. 25, 1748–1756 (2017).
Prockop, D. J. The exciting prospects of new therapies with mesenchymal stromal cells. Cytotherapy 19, 1–8 (2017).
Rama, P. et al. Limbal stem-cell therapy and long-term corneal regeneration. N. Engl. J. Med. 363, 147–155 (2010).
Trounson, A. & McDonald, C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17, 11–22 (2015).
Quarto, R. et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med. 344, 385–386 (2001).
Castro-Manrreza, M. E. & Montesinos, J. J. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J. Immunol. Res. 2015, 394917–394920 (2015).
Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439–1441 (2004).
Casiraghi, F., Perico, N., Cortinovis, M. & Remuzzi, G. Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nat. Rev. Nephrol. 12, 241–253 (2016).
Boregowda, S. V., Booker, C. N. & Phinney, D. G. Mesenchymal stem cells: the moniker fits the science. Stem Cells 36, 7–10 (2018).
Samsonraj, R. M. et al. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl. Med. 6, 2173–2185 (2017).
Galipeau, J. The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15, 2–8 (2013).
Mills, C. R. Osiris Therapeutics Reports Interim Data for COPD Stem Cell Study http://files.shareholder.com/downloads/OSIR/2468414599x0x302507/36275c0d-85b9-4726-a51a-708830588b08/OSIR_News_2009_6_23_General.pdf (Osiris, 2009).
Ankrum, J., Ong, J. F. & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32, 252–260 (2014).
Miyamura, K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. Int. J. Hematol. 103, 155–164 (2016).
Kurtzberg, J. MSB P3 Results For GVHD Presented At ISCT Meeting (Mesoblast, 8 May 2018); http://investorsmedia.mesoblast.com/phoenix.zhtml?c=187006&p=irol-asxnews&t=Search&nyo=0.
Leblanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579–1586 (2008).
Panés, J. et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology 154, 1334–1342.e4 (2018).
Gupta, P. K. et al. Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger’s disease: phase II study report suggests clinical efficacy. Stem Cells Transl. Med. 6, 689–699 (2016).
Sacchetti, B. et al. No identical ‘mesenchymal stem cells’ at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Rep. 6, 897–913 (2016).
Keating, A. Mesenchymal stromal cells: new directions. Stem Cells 10, 709–716 (2012).
Viswanathan, S. et al. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev. 23, 1157–1167 (2014).
Bunnell, B. A., Flaat, M., Gagliardi, C., Patel, B. & Ripoll, C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods 45, 115–120 (2008).
Halfon, S., Abramov, N., Grinblat, B. & Ginis, I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev. 20, 53–66 (2011).
Junker, J. P. E., Sommar, P., Skog, M., Johnson, H. & Kratz, G. Adipogenic, chondrogenic and osteogenic differentiation of clonally derived human dermal fibroblasts. Cells Tissues Organs 191, 105–118 (2010).
Haniffa, M. A. et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J. Immunol. 179, 1595–1604 (2007).
Brandau, S. et al. Orbital fibroblasts from Graves’ orbitopathy patients share functional and immunophenotypic properties with mesenchymal stem/stromal cells. Invest. Ophthalmol. Vis. Sci. 56, 6549–6557 (2015).
Røsland, G. V. et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 69, 5331–5339 (2009).
Prockop, D. J. & Olson, S. D. Clinical trials with adult stem/progenitor cells for tissue repair: let’s not overlook some essential precautions. Blood 109, 3147–3151 (2007).
François, M., Romieu-Mourez, R., Li, M. & Galipeau, J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20, 187–195 (2012).
Serena, C. et al. Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells. Stem Cells 34, 2559–2573 (2016).
Ringdén, O. et al. Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl. Med. 7, 325–331 (2018).
Jung, Y., Bauer, G. & Nolta, J. A. Concise review: induced pluripotent stem cell‐derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells 30, 42–47 (2012).
Gstraunthaler, G., Lindl, T. & van der Valk, J. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology 65, 791–793 (2013).
European Medicine Agency. Guideline on human cell-based medicinal products (CHMP, 2007); https://www.ema.europa.eu/documents/scientific-guideline/guideline-human-cell-based-medicinal-products_en.pdf.
European Medicines Agency. Guideline on the use of bovine serum in the manufacture of human biological medicinal products (CHMP, 2013); https://www.ema.europa.eu/documents/scientific-guideline/guideline-use-bovine-serum-manufacture-human-biological-medicinal-products_en.pdf.
Dimasi, L. Meeting increased demands on cell-based processes by using defined media supplements. BioProcess Int. 9, 48–57 (2011).
Burnouf, T., Strunk, D., Koh, M. B. C. & Schallmoser, K. Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 76, 371–387 (2016).
Doucet, C. et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J. Cell. Physiol. 205, 228–236 (2005).
Abdelrazik, H., Spaggiari, G. M., Chiossone, L. & Moretta, L. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur. J. Immunol. 41, 3281–3290 (2011).
Oikonomopoulos, A. et al. Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci. Rep. 5, 16570 (2015).
Chase, L. G., Lakshmipathy, U., Solchaga, L. A., Rao, M. S. & Vemuri, M. C. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res. Ther. 1, 8 (2010).
Usta, S. N., Scharer, C. D., Xu, J., Frey, T. K. & Nash, R. J. Chemically defined serum-free and xeno-free media for multiple cell lineages. Ann. Transl. Med. 2, 97 (2014).
Kratchmarova, I., Blagoev, B., Haack-Sorensen, M., Kassem, M. & Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308, 1472–1477 (2005).
Ng, F. et al. PDGF, TGF-β, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112, 295–307 (2008).
Lee, M.-S. et al. Enhanced cell growth of adipocyte-derived mesenchymal stem cells using chemically-defined serum-free media. Int. J. Mol. Sci. 18, 1779 (2017).
Agata, H. et al. Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem. Biophys. Res. Commun. 382, 353–358 (2009).
Simon, M. C. & Keith, B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 9, 285–296 (2008).
Das, B. et al. HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. Stem Cells 30, 1685–1695 (2012).
Rosová, I., Dao, M., Capoccia, B., Link, D. & Nolta, J. A. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26, 2173–2182 (2008).
Cerrada, I. et al. Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymal stem cells-mediated cardiac repair. Stem Cells Dev. 22, 501–511 (2013).
Nold, P. et al. Immunosuppressive capabilities of mesenchymal stromal cells are maintained under hypoxic growth conditions and after gamma irradiation. Cytotherapy 17, 152–162 (2015).
Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).
Murphy, W. L., McDevitt, T. C. & Engler, A. J. Materials as stem cell regulators. Nat. Mater. 13, 547–557 (2014).
Li, C. X. et al. MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Nat. Mater. 16, 379–389 (2017).
Huebsch, N. et al. Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate. Nat. Mater. 9, 518–526 (2010).
Shakouri-Motlagh, A., O’Connor, A. J., Brennecke, S. P., Kalionis, B. & Heath, D. E. Native and solubilized decellularized extracellular matrix: a critical assessment of their potential for improving the expansion of mesenchymal stem cells. Acta Biomater. 55, 1–12 (2017).
Yeh, H.-Y., Liu, B.-H. & Hsu, S.-H. The calcium-dependent regulation of spheroid formation and cardiomyogenic differentiation for MSCs on chitosan membranes. Biomaterials 33, 8943–8954 (2012).
Khetan, S. et al. Degradation-mediated cellular traction directs stem cell fate in covalently crosslinked three-dimensional hydrogels. Nat. Mater. 12, 458–465 (2013).
Haugh, M. G. & Heilshorn, S. C. Integrating concepts of material mechanics, ligand chemistry, dimensionality and degradation to control differentiation of mesenchymal stem cells. Curr. Opin. Solid State Mater. Sci. 20, 171–179 (2016).
Lam, A. T.-L. et al. Biodegradable poly-ε-caprolactone microcarriers for efficient production of human mesenchymal stromal cells and secreted cytokines in batch and fed-batch bioreactors. Cytotherapy 19, 419–432 (2017).
Jun, I. et al. Transfer stamping of human mesenchymal stem cell patches using thermally expandable hydrogels with tunable cell-adhesive properties. Biomaterials 54, 44–54 (2015).
Kobayashi, J. & Okano, T. Fabrication of a thermoresponsive cell culture dish: a key technology for cell sheet tissue engineering. Sci. Technol. Adv. Mater. 11, 014111 (2010).
Nagase, K., Yamato, M., Kanazawa, H. & Okano, T. Poly(N-isopropylacrylamide)-based thermoresponsive surfaces provide new types of biomedical applications. Biomaterials 153, 27–48 (2018).
Barckhausen, C. et al. GMP-compliant expansion of clinical-grade human mesenchymal stromal/stem cells using a closed hollow fiber bioreactor. Methods Mol. Biol. 1416, 389–412 (2016).
Food and Drug Administration Guidance for Industry: CGMP for Phase 1 Investigational Drugs (July, 2008); https://www.fda.gov/downloads/drugs/guidances/ucm070273.pdf.
Food and Drug Administration Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing–Current Good Manufacturing Practice (September 2004); http://academy.gmp-compliance.org/guidemgr/files/ASEPT_PROCESS_5882FNL.PDF.
Brindley, D. et al. Cell therapy bioprocessing technologies and indicators of technological convergence. Bioprocess. Int. (1 March 2014).
Roobrouck, V. D., Vanuytsel, K. & Verfaillie, C. M. Concise review: culture mediated changes in fate and/or potency of stem cells. Stem Cells 29, 583–589 (2011).
Shekaran, A. et al. Enhanced in vitro osteogenic differentiation of human fetal MSCs attached to 3D microcarriers versus harvested from 2D monolayers. BMC Biotechnol. 15, 102 (2015).
Banfi, A. et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells. Exp. Hematol. 28, 707–715 (2000).
Bunpetch, V., Wu, H., Zhang, S. & Ouyang, H. From ‘bench to bedside’: current advancement on large-scale production of mesenchymal stem cells. Stem Cells Dev. 26, 1662–1673 (2017).
Rashedi, I. et al. Collagen scaffold enhances the regenerative properties of mesenchymal stromal cells. PLoS ONE 12, e0187348 (2017).
Petrenko, Y., Syková, E. & Kubinová, Š. The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids. Stem Cell Res. Ther. 8, 94 (2017).
Mo, M., Zhou, Y., Li, S. & Wu, Y. Three-dimensional culture reduces cell size by increasing vesicle excretion. Stem Cells 36, 286–292 (2018).
Spees, J. L. et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol. Ther. 9, 747–756 (2004).
Karnieli, O. et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy 19, 155–169 (2017).
Thirumala, S., Wu, X., Gimble, J. M. & Devireddy, R. V. Evaluation of polyvinylpyrrolidone as a cryoprotectant for adipose tissue-derived adult stem cells. Tissue Eng. Part C Methods 16, 783–792 (2010).
Chinnadurai, R. et al. Mesenchymal stromal cells derived from Crohn’s patients deploy indoleamine 2,3-dioxygenase-mediated immune suppression, independent of autophagy. Mol. Therapy 23, 1248–1261 (2015).
François, M. et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy 14, 147–152 (2012).
Moll, G. et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells 32, 2430–2442 (2014).
Chabot, D., Tremblay, T., Paré, I., Bazin, R. & Loubaki, L. Transient warming events occurring after freezing impairs umbilical cord-derived mesenchymal stromal cells functionality. Cytotherapy 19, 978–989 (2017).
Gramlich, O. W. et al. Cryopreserved mesenchymal stromal cells maintain potency in a retinal ischemia/reperfusion injury model: toward an off-the-shelf therapy. Sci. Rep. 6, 26463 (2016).
Chinnadurai, R. et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFN licensing. Stem Cells 34, 2429–2442 (2016).
Burand, A. J., Gramlich, O. W., Brown, A. J. & Ankrum, J. Function of cryopreserved mesenchymal stromal cells with and without interferon-γ prelicensing is context dependent. Stem Cells 35, 1437–1439 (2017).
Woods, E. J., Thirumala, S., Badhe-Buchanan, S. S., Clarke, D. & Mathew, A. J. Off the shelf cellular therapeutics: factors to consider during cryopreservation and storage of human cells for clinical use. Cytotherapy 18, 697–711 (2016).
Dankilkovitch, A. Innovation on the shelf: solving the puzzle of live-cell preservation. https://biopharmadealmakers.nature.com/users/36963-osiris-therapeutics/posts/16532-innovation-on-the-shelf-solving-the-puzzle-of-live-cell-preservation (9 May 2018).
Chinnadurai, R. et al. Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep. 22, 2504–2517 (2018).
Bravery, C. A. et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 15, 9–19 (2013).
Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54–63 (2009).
Block, T. J. et al. Restoring the quantity and quality of elderly human mesenchymal stem cells for autologous cell-based therapies. Stem Cell Res. Ther 8, 239 (2017).
Sun, Y. et al. Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB J. 25, 1474–1485 (2011).
Klinker, M. W., Marklein, R. A., Lo Surdo, J. L., Wei, C.-H. & Bauer, S. R. Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity. Proc. Natl Acad. Sci. USA 114, E2598–E2607 (2017).
Zhu, H. et al. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Stem Cells 24, 928–935 (2006).
Moraes, D. A. et al. A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. Stem Cell Res. Ther. 7, 97 (2016).
Corradetti, B. et al. Hyaluronic acid coatings as a simple and efficient approach to improve MSC homing toward the site of inflammation. Sci. Rep. 7, 7991 (2017).
Venkatesha, S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642–649 (2006).
Amarnath, S. et al. Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cell 33, 1200–1212 (2015).
Salmi, M. & Jalkanen, S. Cell-surface enzymes in control of leukocyte trafficking. Nat. Rev. Immunol. 5, 760–771 (2005).
Ode, A. et al. CD73 and CD29 concurrently mediate the mechanically induced decrease of migratory capacity of mesenchymal stromal cells. Eur. Cell Mater. 22, 26–42 (2011).
Jin, H. J. et al. Downregulation of melanoma cell adhesion molecule (MCAM/CD146) accelerates cellular senescence in human umbilical cord blood-derived mesenchymal stem cells. Stem Cells Transl. Med. 5, 427–439 (2016).
Giuliani, M. et al. TLR ligands stimulation protects MSC from NK killing. Stem Cells 32, 290–300 (2014).
Schallmoser, K. et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng. Part C Methods 14, 185–196 (2008).
Gatta, V. et al. Gene expression modifications in Wharton’s Jelly mesenchymal stem cells promoted by prolonged in vitro culturing. BMC Genom. 14, 635 (2013).
Angelucci, S. et al. Proteome analysis of human Wharton’s jelly cells during in vitro expansion. Proteome Sci. 8, 18 (2010).
Ankrum, J., Dastidar, R. G., Ong, J. F., Levy, O. & Karp, J. M. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Sci. Rep. 4, 4645 (2014).
von Bahr, L. et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol. Blood Marrow Transplant. 18, 557–564 (2012).
Kretlow, J. D. et al. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol. 9, 60 (2008).
Bonab, M. M. et al. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 7, 14 (2006).
Eggenhofer, E. et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 3, 297 (2012).
Cornélio, D. A., Tavares, J. C. M., de A. Pimentel, T. V. C., Cavalcanti, G. B. Jr & Batistuzzo de Medeiros, S. R. Cytokinesis-block micronucleus assay adapted for analyzing genomic instability of human mesenchymal stem cells. Stem Cells Dev. 23, 823–838 (2014).
Stolzing, A., Jones, E., McGonagle, D. & Scutt, A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev. 129, 163–173 (2008).
Bakopoulou, A. et al. Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects ‘stemness’ properties. Stem Cell Res. Ther. 8, 247 (2017).
van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014).
Turinetto, V., Vitale, E. & Giachino, C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int. J. Mol. Sci. 17, 1164 (2016).
Matjusaitis, M., Chin, G., Sarnoski, E. A. & Stolzing, A. Biomarkers to identify and isolate senescent cells. Ageing Res. Rev. 29, 1–12 (2016).
Özcan, S. et al. Unbiased analysis of senescence associated secretory phenotype (SASP) to identify common components following different genotoxic stresses. Aging 8, 1316–1329 (2016).
Severino, V. et al. Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell Death Dis. 4, e911 (2013).
Minieri, V. et al. Persistent DNA damage-induced premature senescence alters the functional features of human bone marrow mesenchymal stem cells. J. Cell. Mol. Med. 19, 734–743 (2015).
Wagner, W. et al. How to track cellular aging of mesenchymal stromal cells? Aging 2, 224–230 (2010).
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123, 966–972 (2013).
Lei, Q. et al. Microvesicles as potential biomarkers for the identification of senescence in human mesenchymal stem cells. Theranostics 7, 2673–2689 (2017).
Griffiths, S., Baraniak, P. R., Copland, I. B., Nerem, R. M. & McDevitt, T. C. Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation in vitro. Cytotherapy 15, 1469–1483 (2013).
Willis, G. R., Kourembanas, S. & Mitsialis, S. A. Therapeutic applications of extracellular vesicles: perspectives from newborn medicine. Methods Mol. Biol. 1660, 409–432 (2017).
Ferguson, S. W. et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci. Rep. 8, 1419 (2018).
Lopez-Verrilli, M. A. et al. Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth. Neuroscience 320, 129–139 (2016).
Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542–1555 (2013).
Lu, Z., Chen, Y., Dunstan, C., Roohani-Esfahani, S. & Zreiqat, H. Priming adipose stem cells with tumor necrosis factor-alpha preconditioning potentiates their exosome efficacy for bone regeneration. Tissue Eng. Part A 23, 1212–1220 (2017).
Hazawa, M. et al. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. Biochem. Biophys. Res. Commun. 446, 1165–1171 (2014).
Monticelli, S. & Natoli, G. Short-term memory of danger signals and environmental stimuli in immune cells. Nat. Immunol. 14, 777–784 (2013).
Bernardo, M. E. & Fibbe, W. E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13, 392–402 (2013).
Prockop, D. J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 31, 2042–2046 (2013).
Bartosh, T. J., Ylostalo, J. H., Bazhanov, N., Kuhlman, J. & Prockop, D. J. Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspase-dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1). Stem Cells 31, 2443–2456 (2013).
Németh, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42–49 (2009).
Kota, D. J., Wiggins, L. L., Yoon, N. & Lee, R. H. TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes 62, 2048–2058 (2013).
Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y. & Prockop, D. J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 118, 330–338 (2011).
Yang, Z. et al. Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation. Sci. Rep. 6, 30263 (2016).
Gonzalez, Y. I. R., Lynch, P. J., Thompson, E. E., Stultz, B. G. & Hursh, D. A. In vitro cytokine licensing induces persistent permissive chromatin at the indoleamine 2,3-dioxygenase promoter. Cytotherapy 18, 1114–1128 (2016).
Waterman, R. S., Tomchuck, S. L., Henkle, S. L. & Betancourt, A. M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5, e10088 (2010).
Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726–736 (2008).
Wang, X. et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Rep. 3, 115–130 (2014).
Killer, M. C. et al. Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid. Stem Cell Res. Ther. 8, 100 (2017).
Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141–150 (2008).
Polchert, D. et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38, 1745–1755 (2008).
Boland, L. et al. IFN-γ and TNF-α pre-licensing protects mesenchymal stromal cells from the pro-inflammatory effects of palmitate. Mol. Ther. 26, 860–873 (2018).
Zimmermann, J. A., Hettiaratchi, M. H. & McDevitt, T. C. Enhanced immunosuppression of T cells by sustained presentation of bioactive interferon-γ within three-dimensional mesenchymal stem cell constructs. Stem Cells Transl. Med. 6, 223–237 (2017).
Lee, M. W. et al. Strategies to improve the immunosuppressive properties of human mesenchymal stem cells. Stem Cell Res. Ther. 6, 179 (2015).
Fayyad-Kazan, M., Najar, M., Fayyad-Kazan, H., Raicevic, G. & Lagneaux, L. Identification and evaluation of new immunoregulatory genes in mesenchymal stromal cells of different origins: comparison of normal and inflammatory conditions. Med. Sci. Monitor Basic Res. 23, 87–96 (2017).
Barrachina, L. et al. Priming equine bone marrow-derived mesenchymal stem cells with proinflammatory cytokines: implications in immunomodulation–immunogenicity balance, cell viability, and differentiation potential. Stem Cells Dev. 26, 15–24 (2017).
Ylostalo, J. H., Bartosh, T. J., Tiblow, A. & Prockop, D. J. Unique characteristics of human mesenchymal stromal/progenitor cells pre-activated in 3-dimensional cultures under different conditions. Cytotherapy 16, 1486–1500 (2014).
Tsai, A.-C., Liu, Y., Yuan, X. & Ma, T. Compaction, fusion, and functional activation of three-dimensional human mesenchymal stem cell aggregate. Tissue Eng. Part A 21, 1705–1719 (2015).
Chen, H.-Y. et al. The protective effect of 17β-estradiol against hydrogen peroxide-induced apoptosis on mesenchymal stem cell. Biomed. Pharmacother. 66, 57–63 (2012).
Block, G. J. et al. Multipotent stromal cells (MSCs) are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1 (STC-1). Stem Cells 27, 670–681 (2009).
Casado, J. G., Tarazona, R. & Sanchez-Margallo, F. M. NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity. Stem Cell Rev. 9, 184–189 (2013).
El Haddad, N. et al. The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. J. Immunol. 187, 2252–2260 (2011).
Hsu, S.-H. & Huang, G.-S. Substrate-dependent Wnt signaling in MSC differentiation within biomaterial-derived 3D spheroids. Biomaterials 34, 4725–4738 (2013).
Chan, J. A., Krichevsky, A. M. & Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029–6033 (2005).
Mahrouf-Yorgov, M. et al. Mesenchymal stem cells sense mitochondria released from damaged cells as danger signals to activate their rescue properties. Cell Death Differ. 24, 1224–1238 (2017).
Naji, A. et al. Rationale for determining the functional potency of mesenchymal stem cells in preventing regulated cell death for therapeutic use. Stem Cells Transl. Med. 6, 713–719 (2017).
Lai, R. C. et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 4, 214–222 (2010).
Tomasoni, S. et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 22, 772–780 (2013).
Wang, X. et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation 122, 1308–1318 (2010).
Yamamoto, H. et al. MicroRNA-494 regulates mitochondrial biogenesis in skeletal muscle through mitochondrial transcription factor A and Forkhead box j3. Am. J. Physiol. Endocrinol. Metab. 303, E1419–E1427 (2012).
Karp, J. M. & Leng Teo, G. S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4, 206–216 (2009).
Kidd, S. et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27, 2614–2623 (2009).
Rombouts, W. J. C. & Ploemacher, R. E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 17, 160–170 (2003).
Levy, O. et al. A small-molecule screen for enhanced homing of systemically infused cells. Cell Rep. 10, 1261–1268 (2015).
Teo, G. S. L. et al. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 30, 2472–2486 (2012).
Nitzsche, F. et al. Concise review: MSC adhesion cascade—insights into homing and transendothelial migration. Stem Cells 35, 1446–1460 (2017).
Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678–689 (2007).
Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10, 858–864 (2004).
Tang, Y. L. et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ. Res. 104, 1209–1216 (2009).
Guan, S. P. et al. Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex. FEBS Open Bio 8, 15–26 (2018).
Liu, N., Tian, J., Cheng, J. & Zhang, J. Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment. Exp. Cell Res. 319, 2019–2027 (2013).
Sarkar, D. et al. Engineered cell homing. Blood 118, e184–e191 (2011).
Sarkar, D. et al. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials 31, 5266–5274 (2010).
Sarkar, D. et al. Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjug. Chem. 19, 2105–2109 (2008).
Rüster, B. et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108, 3938–3944 (2006).
Ip, J. E. et al. Mesenchymal stem cells use integrin β1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol. Biol. Cell 18, 2873–2882 (2007).
Delorme, B. et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 27, 1142–1151 (2009).
Leong, W. S. et al. Cyclic tensile loading regulates human mesenchymal stem cell differentiation into neuron-like phenotype. J. Tissue Eng. Regen. Med. 6(Suppl. 3), s68–s79 (2012).
Cheng, L.-C., Pastrana, E., Tavazoie, M. & Doetsch, F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 12, 399–408 (2009).
Frith, J. E. et al. Mechanically-sensitive miRNAs bias human mesenchymal stem cell fate via mTOR signalling. Nat. Commun. 9, 257 (2018).
Boregowda, S. V. & Phinney, D. G. Quantifiable metrics for predicting MSC therapeutic efficacy. J. Stem Cell Res. Ther. 6, 365 (2016).
Galipeau, J. et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18, 151–159 (2016).
McLeod, C. M. & Mauck, R. L. On the origin and impact of mesenchymal stem cell heterogeneity: new insights and emerging tools for single cell analysis. Eur. Cell Mater. 34, 217–231 (2017).
Goodell, M. A., Nguyen, H. & Shroyer, N. Somatic stem cell heterogeneity: diversity in the blood, skin and intestinal stem cell compartments. Nat. Rev. Mol. Cell Biol. 16, 299–309 (2015).
Berglund, A. K., Fortier, L. A., Antczak, D. F. & Schnabel, L. V. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res. Ther. 8, 288 (2017).
Zangi, L. et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cell 27, 2865–2874 (2009).
Isakova, I. A. et al. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. PLoS ONE 9, e87238 (2014).
de Witte, S. F. H. et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells 36, 602–615 (2018).
Spees, J. L., Lee, R. H. & Gregory, C. A. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res. Ther. 7, 125 (2016).
Zhang, Y., Chen, S. & Pei, M. Biomechanical signals guiding stem cell cartilage engineering: from molecular adaption to tissue functionality. Eur. Cell Mater. 31, 59–78 (2016).
Horwitz, E. M. et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5, 309–313 (1999).
Galleu, A. et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci. Transl. Med. 9, eaam7828 (2017).
Brooks, A. et al. Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells. Stem Cells Transl. Med. 7, 78–86 (2018).
Schäffler, A. & Büchler, C. Concise review: adipose tissue-derived stromal cells—basic and clinical implications for novel cell-based therapies. Stem Cell 25, 818–827 (2007).